Clinical characteristics | Mean±SD/Positive (%) | Nominal p value | |
High 2019 criteria score (n=59) | Low 2019 criteria score (n=61) | ||
Age | 35.83±12.66 | 34.93±13.38 | 0.705 |
Sex, male/female | 14/45 | 6/55 | 0.051 |
Disease duration, months | 1.0 (0.5, 6.0) | 1.0 (0.5, 3.0) | 0.141 |
SLEDAI | 21.12±4.80 | 16.34±4.61 | 0.0001 |
2019 criteria score | 30.40±3.92 | 19.95±10.27 | 0.0001 |
Class II or V lupus nephritis | 9 (5.25%) | 24 (39.34%) | 0.003 |
Class III or IV lupus nephritis | 50 (84.75%) | 37 (60.66%) | |
Fever | 18 (30.51%) | 9 (14.75%) | 0.039 |
Mucocutaneous domain | |||
Acute cutaneous lupus | 27 (45.76%) | 5 (8.20%) | 0.003 |
Subacute cutaneous lupus or discoid rash | 2 (3.39%) | 0 | 0.240 |
Non-scarring alopecia | 10 (16.95%) | 3 (4.92%) | 0.042 |
Oral ulcer | 4 (6.78%) | 0 | 0.055 |
Musculoskeletal domain | 17 (35.59%) | 4 (6.56%) | 0.002 |
Serosal domain | 27 (45.76%) | 7 (11.48%) | <0.0001 |
Neuropsychiatric domain | 2 (3.39%) | 1 (1.64%) | 0.616 |
Haematological domain | |||
Leucopoenia | 35 (59.32%) | 19 (31.15%) | 0.002 |
Thrombocytopenia | 21 (35.59%) | 5 (8.20%) | 0.002 |
Autoimmune haemolysis | 7 (11.86%) | 1 (1.64%) | 0.031 |
Laboratory criteria | |||
Anti-β2GP1 antibodies or lupus anticoagulant* | 17 (28.81%) | 15 (24.59%) | 0.601 |
Low complement | |||
C3 | 58 (98.31%) | 47 (77.05%) | 0.0005 |
C4 | 53 (89.83%) | 41 (67.21%) | 0.0026 |
Anti-dsDNA antibody | 48 (81.36%) | 20 (32.79%) | <0.0001 |
Anti-Sm antibody | 24 (40.68%) | 16 (26.23%) | 0.0932 |
P-values <0.05 were considered as significance and marked in bold.
*The data of lupus anticoagulant were absent.
SLEDAI, SLE disease activity index.